Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_04277 |
| Species: | Homo sapiens |
| Position : | chr11:5301862-5302715 |
| Year: | 2003 |
| Title: | A human globin enhancer causes both discrete and widespread alterations in chromatin structure. |
| Genome Build: | hg19 |
| Enhancer Type: | Enhancer |
| Condition: | Normal |
| PMID: | 14585970 |
| Tissue: | blood |
| Tissue Ontology ID: | UBERON:0000178 |
| Cell Source: | K-562 |
| CVCL ID: | CVCL_0004 |
| Cell Type: | malignant cell |
| Cell Ontology ID: | CL:0001064 |
| Experiment Type: | Enhancer activity assay; chromatin accessibility assay; chromatin modification assay; In vivo functional validation |
| Low Throughput Method: | NF-E2-site mutagenesis; DNase I hypersensitivity assay; restriction enzyme accessibility assay; MNase mapping; ChIP; RNase protection assay; In vivo phenotyping |
| Target gene : | HBE1 |
| TF name : | NFE2 |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| NFE2 | Factors involved in megakaryocyte development and platelet production | reactome | 111 |
| Enhancer ID | Position | Tissue | Cell | Disease |
|---|---|---|---|---|
| E_02356 | chr11:5222500-5323700 | blood | erythroid cell | NA |
| E_02363 | chr11:5222500-5323700 | blood | erythroid cell | NA |
| E_02364 | chr11:5222500-5323700 | blood | erythroid cell | NA |
| E_02365 | chr11:5222500-5323700 | blood | erythroid cell | NA |
| E_03631 | chr11:5301485-5302895 | blood | malignant cell | NA |
| E_03230 | chr11:5301600-5302400 | blood / hematopoietic system | NA | NA |
| E_03231 | chr11:5301600-5302400 | blood / hematopoietic system | NA | NA |
| E_03232 | chr11:5301600-5302400 | blood / hematopoietic system | NA | NA |
| E_03070 | chr11:5301801-5302175 | pleural effusion | erythroid lineage cell | NA |
| E_03071 | chr11:5301801-5302175 | pleural effusion | erythroid lineage cell | NA |
| E_03200 | chr11:5301862-5302715 | blood | malignant cell | NA |
| E_03201 | chr11:5301862-5302715 | blood | malignant cell | NA |
| E_03202 | chr11:5301862-5302715 | blood | malignant cell | NA |
| E_03203 | chr11:5301862-5302715 | blood | malignant cell | NA |
| E_03204 | chr11:5301862-5302715 | blood | malignant cell | NA |
| E_03205 | chr11:5301862-5302715 | blood | malignant cell | NA |
| E_03206 | chr11:5301862-5302715 | blood | malignant cell | NA |
| E_03207 | chr11:5301862-5302715 | blood | malignant cell | NA |
| E_03210 | chr11:5301862-5302715 | blood | erythroid-like cell | NA |
| E_03211 | chr11:5301862-5302715 | blood | erythroid-like cell | NA |
| E_03212 | chr11:5301862-5302715 | blood | erythroid-like cell | NA |
| E_03213 | chr11:5301862-5302715 | blood | erythroid-like cell | NA |
| E_04382 | chr11:5301862-5302715 | blood | malignant cell | NA |
| E_04567 | chr11:5301862-5302715 | blood | myeloid cell | NA |
| E_04237 | chr11:5301983-5302001 | pleural effusion | erythroid lineage cell | NA |
| E_04238 | chr11:5301983-5302001 | pleural effusion | erythroid lineage cell | NA |
| E_04245 | chr11:5301983-5302001 | uterine cervix | epithelial cell | NA |
| E_04246 | chr11:5301983-5302001 | uterine cervix | epithelial cell | NA |